Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Dr. Reddy's Laboratories Ltd ADR (RDY)

Dr. Reddy's Laboratories Ltd ADR (RDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,424,874
  • Shares Outstanding, K 166,893
  • Annual Sales, $ 3,350 M
  • Annual Income, $ 668,000 K
  • 60-Month Beta 0.55
  • Price/Sales 3.97
  • Price/Cash Flow 15.53
  • Price/Book 3.90
Trade RDY with:

Options Overview Details

View History
  • Implied Volatility 30.34% ( +3.67%)
  • Historical Volatility 20.85%
  • IV Percentile 83%
  • IV Rank 70.38%
  • IV High 38.28% on 10/18/23
  • IV Low 11.47% on 08/30/23
  • Put/Call Vol Ratio 1.00
  • Today's Volume 4
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 282
  • Open Int (30-Day) 344

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 1.10
  • Number of Estimates 1
  • High Estimate 1.10
  • Low Estimate 1.10
  • Prior Year 1.03
  • Growth Rate Est. (year over year) +6.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.52 +11.22%
on 06/18/24
80.79 -2.92%
on 07/15/24
+6.58 (+9.16%)
since 06/14/24
3-Month
68.07 +15.22%
on 05/31/24
80.79 -2.92%
on 07/15/24
+6.82 (+9.52%)
since 04/16/24
52-Week
62.68 +25.13%
on 07/18/23
80.79 -2.92%
on 07/15/24
+16.53 (+26.70%)
since 07/14/23

Most Recent Stories

More News
2 overlooked stocks that crushed earnings but traded lower

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

BMY : 41.13 (+2.44%)
WHR : 111.82 (+1.04%)
BAC : 44.14 (+5.37%)
DB : 16.56 (-0.06%)
HSBC : 43.46 (+0.49%)
NVS : 110.47 (+0.13%)
PFE : 29.43 (+1.13%)
TEVA : 16.72 (-2.11%)
RDY : 78.37 (-2.57%)
Chart of the Day: What's Cooking at Dr. Reddy's Lab

The Chart of the Day belongs to integrated drug company Dr. Reddy's Laboratories (RDY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy...

RDY : 78.37 (-2.57%)
Drugmaker GSK: Becoming a Healthier Value Stock

Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit.

GSK : 38.92 (+0.65%)
RDY : 78.37 (-2.57%)
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Regadenoson Injection...

RDY : 78.37 (-2.57%)
Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Treprostinil Injection...

RDY : 78.37 (-2.57%)
Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan

Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce...

RDY : 78.37 (-2.57%)
ADTX : 1.5981 (+5.83%)
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance function of Regulatory T Cells...

RDY : 78.37 (-2.57%)
COYA : 7.65 (-0.65%)
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

RDY : 78.37 (-2.57%)
COYA : 7.65 (-0.65%)
Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio

Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr....

RDY : 78.37 (-2.57%)
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global’s Sustainability Yearbook for the 3rd year

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”) announced major back-to-back recognitions in gender equality and sustainability....

RDY : 78.37 (-2.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through...

See More

Key Turning Points

3rd Resistance Point 82.44
2nd Resistance Point 81.61
1st Resistance Point 81.03
Last Price 78.37
1st Support Level 79.62
2nd Support Level 78.79
3rd Support Level 78.21

See More

52-Week High 80.79
Last Price 78.37
Fibonacci 61.8% 73.87
Fibonacci 50% 71.74
Fibonacci 38.2% 69.60
52-Week Low 62.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar